New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in humans. A NIH funded study by Cardiology Division and Mitochondria & Metabolism Center at the University of Washington, published in The Journal of Clinical Investigation, found that Niagen supplementation reduced signs of inflammation, specifically inflammatory cytokin
Click here to view original post